Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| INKT | PRESS-RELEASE | neutral | 3/10 | MiNK Therapeutics announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, in combination | Apr 1, 2026 |
| FTLF | PRESS-RELEASE | mixed | 6/10 | FitLife Brands reported strong top-line growth in Q4 and full-year 2025, driven by the Irwin Naturals acquisition, with | Apr 1, 2026 |
| RAPP | PRESS-RELEASE | neutral | 3/10 | Rapport Therapeutics announced upcoming presentation of Phase 2a data for its lead candidate RAP-219 in focal onset seiz | Apr 1, 2026 |
| OCUL | PRESS-RELEASE | neutral | 3/10 | Ocular Therapeutix announced upcoming presentations of Phase 3 data for its investigational therapy AXPAXLI™ (OTX-TKI) i | Apr 1, 2026 |
| FBLG | PRESS-RELEASE | bearish | 6/10 | FibroBiologics (FBLG) announced the pricing of a $3 million public offering of 2.27 million shares and warrants to purch | Mar 31, 2026 |
| ERNA | PRESS-RELEASE | bullish | 7/10 | Ernexa Therapeutics announced preclinical success for its lead candidate ERNA-101 in ovarian cancer, with plans to submi | Mar 31, 2026 |
| CVKD | PRESS-RELEASE | mixed | 6/10 | Cadrenal Therapeutics reported financial results for Q4 and full year 2025, highlighting a $3.0M net loss for the quarte | Mar 31, 2026 |
| ONCO | PRESS-RELEASE | neutral | 4/10 | Onconetix announced the appointment of David White as CEO and Sammy Dorf to its Board of Directors and Audit Committee, | Mar 31, 2026 |
| FF | PRESS-RELEASE | mixed | 5/10 | FutureFuel Corp. (FF) has cut its quarterly dividend from prior levels to $0.01 per share and will redirect capital towa | Mar 31, 2026 |
| PTHS | PRESS-RELEASE | neutral | 5/10 | Pelthos Therapeutics announced the first patient dosed in a Phase 1b/2a trial for CT2000, a novel eye drop targeting NaV | Mar 31, 2026 |
| ALLR | PRESS-RELEASE | bullish | 7/10 | Allarity Therapeutics reported its 2025 financial results, highlighting a $14.7 million cash position, $320K in license | Mar 31, 2026 |
| NGEN | PRESS-RELEASE | mixed | 6/10 | NervGen Pharma reported full-year 2025 financial results and provided clinical updates, including completion of its End- | Mar 31, 2026 |
| ELAB | PRESS-RELEASE | neutral | 4/10 | PMGC Holdings Inc. (ELAB) announced that its subsidiary AGA Precision Systems secured a 5-year long-term supply agreemen | Mar 31, 2026 |
| INKT | PRESS-RELEASE | mixed | 5/10 | MiNK Therapeutics reported financial results for Q4 and full year 2025, highlighting a net loss increase to $12.5M but i | Mar 31, 2026 |
| PVLA | PRESS-RELEASE | bullish | 8/10 | Palvella Therapeutics reported full-year 2025 financial results and provided a significant corporate update highlighting | Mar 31, 2026 |
| SXTP | PRESS-RELEASE | mixed | 5/10 | Sixty Degrees Pharmaceuticals reported FY2025 net product revenue growth of 65% to $1.005 million, driven by higher sale | Mar 31, 2026 |
| BMEA | PRESS-RELEASE | bullish | 7/10 | Biomea Fusion announced the first patient dosed in two Phase II trials (COVALENT-211 and COVALENT-212) evaluating icovam | Mar 31, 2026 |
| BIIB | PRESS-RELEASE | bullish | 7/10 | Biogen announced the acquisition of Apellis Pharmaceuticals for $41 per share in cash, totaling $5.6 billion in upfront | Mar 31, 2026 |
| SCYX | PRESS-RELEASE | bullish | 7/10 | Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a clinical-stage oral therapy for autosomal dominant | Mar 31, 2026 |
| CURX | PRESS-RELEASE | neutral | 3/10 | Curanex Pharmaceuticals issued a press release highlighting operational progress in advancing its lead asset, Phyto-N, t | Mar 30, 2026 |
| SNYR | PRESS-RELEASE | neutral | 2/10 | Synergy CHC Corp. announced a rescheduled date for its Q4 and full-year 2025 earnings release on April 1, 2026, before m | Mar 30, 2026 |
| ARTL | PRESS-RELEASE | bearish | 6/10 | Artelo Biosciences closed a private placement offering of 3,188,407 shares (or pre-funded warrants) and warrants to purc | Mar 30, 2026 |
| BGMS | PRESS-RELEASE | mixed | 5/10 | Bio Green Med Solution (BGMS) reported a strategic pivot from biopharma to fire safety operations following the acquisit | Mar 30, 2026 |
| FBIO | PRESS-RELEASE | bullish | 8/10 | Fortress Biotech announced the closing of the $205 million sale of a Rare Pediatric Disease Priority Review Voucher (PRV | Mar 30, 2026 |
| RNXT | PRESS-RELEASE | mixed | 6/10 | RenovoRx reported $1.1 million in revenue for 2025, its first full year of commercialization, up from $43,000 in 2024, d | Mar 30, 2026 |
| AEON | PRESS-RELEASE | mixed | 5/10 | AEON Biopharma reported financial results for 2025, highlighted by a net loss of $39.2 million and a cash balance of $3. | Mar 30, 2026 |
| LXEO | PRESS-RELEASE | bullish | 7/10 | Lexeo Therapeutics reported financial results for Q4 and full year 2025, highlighted by a strong cash position of $246.6 | Mar 30, 2026 |
| AKTS | PRESS-RELEASE | bullish | 7/10 | Aktis Oncology announced FDA clearance of IND applications for its AKY-2519 program, enabling a Phase 1b trial in mid-20 | Mar 30, 2026 |
| SGMO | PRESS-RELEASE | mixed | 6/10 | Sangamo Therapeutics reported mixed financial results for 2025, with declining annual revenue and widening net losses, b | Mar 30, 2026 |
| ANNX | PRESS-RELEASE | neutral | 4/10 | Annexon Biosciences reported fourth quarter and full year 2025 financial results, highlighting a strong cash position of | Mar 30, 2026 |